A Multicenter, Open-label Study to Evaluate the Safety and Diagnostic Efficacy of Mangoral in Patients With Known or Suspected Focal Liver Lesions and Severe Renal Impairment

Conditions

Kidney

Phase III

Volunteers
Health Professionals

What is the purpose of this trial?

The overall objective of this study is to evaluate the safety and diagnostic efficacy of Mangoral in liver MRI in patients with known or suspected focal liver lesions and severe renal impairment. The diagnostic efficacy of Mangoral will be assessed in terms of visualization of detected focal liver lesions in combined MRI (CMRI: combined Mangoral-enhanced and unenhanced MRI) compared to unenhanced MRI.

Ages
18 years and older
Gender
Both

Find out more about who can participate in this trial

Trial with
Ascelia Pharma AB
Start Date
01/30/2020
End Date
12/30/2020

For more information about this study, contact:

Kristine Tyc

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Jeffrey Weinreb, MD, FACR, FISMRM, FSABI
Professor of Radiology and Biomedical Imaging; Director, MRI Services; Chief, MRI Service

Last Updated
02/04/2020
Study HIC
#2000026178

A Multicenter, Open-label Study to Evaluate the Safety and Diagnostic Efficacy of Mangoral in Patients With Known or Suspected Focal Liver Lesions and Severe Renal Impairment

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Contact Information